Renal and systemic effects of endothelin-1 in diabetic-hypertensive rats

Effect of anti-Helicobacter pylori treatment on early diabetic kidney disease

AIM: To assess the effect of anti-Helicobacter pylori (H. pylori) therapy on chronic kidney disease (CKD) associated with type 2 diabetes mellitus (T2DM).

METHODS: Seventy-five T2DM patients with newly diagnosed CKD and H. pylori infection were randomly divided into an anti-H. pylori therapy group (n = 39) and a control group (n = 36). All of the patients received routine treatment for three months. Patients in the anti-H. pylori group were additionally given anti-H. pylori therapy. Clinical indices including fasting blood glucose (FBG), 2-h plasma glucose (2-h PG), hemoglobin A1c (HbA1c), systolic blood pressure (SBP), diastolic blood pressure (DBP), cholesterol (TC), triglyceride (TG), urinary albumin/creatitine ratio (UAlb/Cr), C-reactive protein (CRP), tumor necrosis factor α (TNF-α), plasma endothelin 1 (ET-1), and homocysteine (HCY) were recorded before and three months after treatment.

RESULTS: No significant differences were observed in all clinical indices between the two groups before treatment (P > 0.05). The eradication rate of H. pylori in the anti-H. pylori group was significantly higher than that in the control group three months after treatment (P < 0.01). There were no differences in FBG, 2-h PG, SBP, DBP, HbA1c, TG, or TC between before and after treatment (P > 0.05). At three months after treatment, UAlb/Cr, CRP, ET-1, TNF-α and HCY decreased significantly in both groups (P < 0.05), and changes were statistically significant different between the two groups (P < 0.05).

CONCLUSION: Anti-H. pylori therapy is beneficial for T2DM patients with CKD, because it can help control UAlb/Cr, CRP, ET-1, TNF-α, and HCY and even play an important role in postponing CKD.